Firebrick Pharma Expands Nasodine Portfolio with Singapore Throat Spray Launch
Firebrick Pharma (ASX: FRE) has launched the Firebrick Pharma Nasodine Throat Spray in Singapore, marking the product’s first international market entry and a strategic expansion of the company’s upper respiratory care franchise. The 1% povidone-iodine throat spray complements the existing Nasodine Nasal Spray, targeting sore throats that are often the first sign of the common cold.
Manufacturing was completed in Australia during November and December 2025, with shipments arriving in Singapore in early January 2026. The product rollout follows a two-phase strategy: an initial six-month focus on hospitals and healthcare professionals (HCPs), followed by retail channel expansion. Distribution partner Innorini Life Sciences will execute the launch, with the throat spray priced at S$19.99, representing a 20% discount compared to the nasal spray’s S$24.99 retail price.
When big ASX news breaks, our subscribers know first
Market Opportunity
“Following the strong response to Nasodine Nasal Spray in Singapore, we are extremely excited to introduce the Nasodine Throat Spray to the market. This represents a natural extension of the brand and a significant opportunity to strengthen Nasodine as a comprehensive first-line antiseptic solution for upper respiratory care,” said Rishi Nandiraju, Managing Director at Innorini Life Sciences.
Launch Timeline:
- November-December 2025: Commercial manufacturing completed in Australia
- Early January 2026: Product shipment to Singapore
- January 2026: HCP-focused launch phase begins (6-month duration)
- Mid-2026: Retail channel rollout commences
Building a multi-product franchise across multiple markets demonstrates commercialisation capability and derisks single-product dependence.
Why Throat Sprays Matter for Cold and Flu Management
Sore throats are often the first sign of the common cold, making early intervention a priority for symptom management. Throat sprays function as antiseptic barriers, delivering active ingredients directly to affected tissues in the oral cavity and pharynx. Povidone-iodine, the active ingredient in Nasodine Throat Spray, provides broad-spectrum antiseptic activity against bacteria, viruses, and fungi.
The spray format offers distinct advantages over traditional gargle solutions. Each spray delivers approximately 0.2 mL of solution, a volume small enough to eliminate the need for expectoration (spitting out). This contrasts sharply with gargle formats, which require users to swish larger volumes before disposal.
The precise nozzle targeting allows users to direct the antiseptic solution to specific areas of discomfort, whilst the 25mL bottle size supports portability for travel, commuting, and workplace use.
Key Product Benefits:
- Compact, easy-to-use design
- Pleasant-tasting formulation
- Precise nozzle targeting to affected areas
- No staining or expectoration required
Throat spray category addresses high-frequency consumer need with superior convenience profile compared to legacy formats, critical for retail channel penetration.
Strategic Commercialisation Pathway Takes Shape
Singapore Market Execution Plan
Innorini Life Sciences will initially concentrate on building credibility within Singapore’s HCP community over a six-month period before transitioning to retail distribution. This phased approach leverages clinical validation to strengthen brand positioning ahead of direct-to-consumer sales. Singapore’s regulatory framework allows antiseptic products to enter the market without pre-market approval, streamlining the launch timeline compared to Australia’s Therapeutic Goods Administration (TGA) requirements. Firebrick has secured a TGA export permit (ARTG 517465) for the throat spray.
The product is available for online purchase through nasodine-sg.com during the HCP phase. Price positioning reflects local market dynamics, with the throat spray’s S$19.99 retail price offering accessibility whilst maintaining margin structure.
| Product Name | Active Ingredient Concentration | Price (SGD) |
|---|---|---|
| Nasodine Nasal Spray | 0.5% povidone-iodine | $24.99 |
| Nasodine Throat Spray | 1% povidone-iodine | $19.99 |
Multi-Market Expansion Pipeline
Firebrick expects to introduce the throat spray in Fiji and the USA during 2026, following the established footprint of Nasodine Nasal Spray. The nasal spray currently operates in the USA, Singapore, and Fiji & South Pacific markets, with approval being pursued in the Philippines. This geographic expansion strategy leverages existing regulatory pathways and distribution infrastructure, reducing market entry costs and accelerating launch timelines.
Additional Nasodine products are planned for introduction across existing markets in 2026, though specific formulations have not been disclosed. The company’s ability to deploy new products through established channels creates operational efficiencies whilst broadening revenue opportunities.
Multi-market rollout derisks geographic concentration and validates scalable commercialisation model.
Building the Nasodine Franchise Value Proposition
Firebrick’s product development strategy centres on building a defensible upper respiratory care franchise rather than pursuing isolated product launches. The throat spray provides oral cavity protection to complement the nasal spray’s anterior defence mechanism, positioning Nasodine as a comprehensive first-line antiseptic solution. This dual-product approach targets multiple entry points for respiratory pathogens, addressing consumer demand for complete protection during cold and flu season.
The company’s focus on convenient, ready-to-use formats differentiates Nasodine from traditional gargle products that require preparation and expectoration. Both the nasal and throat sprays utilise the same custom-designed 25mL bottle with formulation-specific spray pumps, creating manufacturing efficiencies whilst maintaining consistent brand presentation across the product range.
Franchise Strategy
“We are aiming to build a valuable Nasodine franchise that based multiple products across multiple markets,” said Dr Peter Molloy, Executive Chairman at Firebrick Pharma.
Three Pillars of Franchise Strategy:
- Product range expansion: Developing complementary formulations for nasal and oral use
- Geographic diversification: Launching across USA, Singapore, Fiji, and future markets
- Channel optimisation: Building presence across HCP and retail distribution networks
Franchise approach creates defensible market position and multiple revenue streams from shared research and development and regulatory investments. Platform strategy supports higher valuation multiples than single-product companies.
The next major ASX story will hit our subscribers first
Commercial Partnership Validation with Innorini
Innorini Life Sciences’ decision to expand its product portfolio with the throat spray signals commercial confidence following the nasal spray’s performance in Singapore. As Firebrick’s exclusive licensing partner, Innorini assumes market development costs whilst providing local market expertise and distribution infrastructure. The partner’s commitment to a dual-channel strategy, prioritising HCP credibility-building before retail expansion, mirrors proven pharmaceutical launch methodologies.
The partnership structure reduces Firebrick’s capital requirements for international market development whilst maintaining revenue participation through licensing arrangements. Innorini’s enthusiasm for the throat spray opportunity, as expressed in management commentary, suggests the nasal spray has achieved sufficient market traction to justify portfolio expansion.
Innorini’s Strategic Priorities:
- Building clinical credibility through 6-month HCP engagement phase
- Preparing retail channel infrastructure for consumer launch
- Establishing Nasodine as a trusted household brand in Singapore
Experienced partner’s willingness to expand product portfolio signals commercial traction and reduces Firebrick’s capital requirements for market development.
Want More Biotech Breakthroughs Delivered to Your Inbox?
The Nasodine throat spray launch represents exactly the kind of strategic commercialisation milestone that biotech investors monitor closely. For readers tracking Australian biotech and healthcare innovation, missing the next product approval, regulatory milestone, or partnership announcement could mean overlooking significant market opportunities. StockWire X publishes comprehensive analysis on ASX biotech, healthcare, technology, and financial sector developments—sectors where timing and information quality matter.
The Big News Blast service delivers FREE breaking news alerts plus detailed analysis to over 20,000 investors across non-resource ASX sectors. Unlike basic news feeds, each alert includes context, strategic implications, and market positioning insights. To receive biotech updates, regulatory announcements, and commercialisation milestones as they happen, click the “Free Alerts” button in the menu at StockWire X and join Australia’s most active community of growth sector investors.